Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc logo
ALNY

Alnylam Pharmaceuticals Inc (ALNY)

$223.373.19%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$222.56
Day's Range
$231.5
$117.58
52-Week Range
$231.53
1 month return52.9%
3 month return91.61%
1 year return17.26%
5 year return165.83%

Company Information

Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
OrganizationAlnylam Pharmaceuticals Inc
Employees1453
CEOJohn Maraganore
IndustryHealth Technology

Analyst Recommendation

based on 29 analysts ratings

Buy
72%
Buy
24%
Hold
3%
Sell

Based on 29 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Downside of 7.96%

Current

$223.37

Target

$205.59

Recommendation Trend

Based on 29 analyst

Current1M Ago3M Ago
Buy
21
21
23
Hold
7
6
5
Sell
1
1
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
18.7B
Book Value
4.89
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-7.2
PEG Ratio
-0.49
Wall Street Target Price
210.65

Valuation

Trailing PE0.0
Forward PE0.0
Price/Sales (ttm)
22.15
Price/Book (mrq)
34.27
Enterprise Value
18.7B
Enterprise Value/Revenue
22.17
Enterprise Value/Ebitda
0.0

Technicals

Beta
0.85
50 Day MA
160.17
200 Day MA
174.39

Institutional Holdings

FMR Inc

13.28%

Vanguard Group Inc

8.96%

Baillie Gifford & Co Limited.

8.39%

BlackRock Inc

6.35%

Wellington Management Company LLP

5.82%

T. Rowe Price Associates, Inc.

5.62%

Discover more

Frequently Asked Questions

What is Alnylam Pharmaceuticals Inc share price today?

Can Indians buy Alnylam Pharmaceuticals Inc shares?

How can I buy Alnylam Pharmaceuticals Inc shares from India?

Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Alnylam Pharmaceuticals Inc stocks?

What are today’s High and Low prices of Alnylam Pharmaceuticals Inc?

What are today’s traded volumes of Alnylam Pharmaceuticals Inc?

What is today’s market capitalisation of Alnylam Pharmaceuticals Inc?

What is the 52 Week High and Low Range of Alnylam Pharmaceuticals Inc?

How much percentage Alnylam Pharmaceuticals Inc is down from its 52 Week High?

How much percentage Alnylam Pharmaceuticals Inc is up from its 52 Week low?

What are the historical returns of Alnylam Pharmaceuticals Inc?

Who is the Chief Executive Officer (CEO) of Alnylam Pharmaceuticals Inc?